Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum

Tipranks - Tipranks - Fri Jan 16, 8:16AM CST

Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today and set a price target of $25.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Lowe is a 4-star analyst with an average return of 8.0% and a 42.86% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Rezolute, Palvella Therapeutics, and Eupraxia Pharmaceuticals.

In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

See the top stocks recommended by analysts >>

Based on Actuate Therapeutics, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.41 million. In comparison, last year the company had a GAAP net loss of $5.97 million

Read More on ACTU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).